Delguste C, Amory H, Doucet M, Piccot-Crézollet C, Thibaud D, Garnero P, Detilleux J, Lepage O M
Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Liege, Belgium.
Bone. 2007 Sep;41(3):414-21. doi: 10.1016/j.bone.2007.05.005. Epub 2007 May 23.
Tiludronate, a bisphosphonate, has recently been introduced in veterinary medicine to treat orthopedic conditions in the horse. This study was designed to evaluate its effects on biochemical biomarkers of bone metabolism and on bone density and structure in an experimental model of disuse osteoporosis induced by cast application in horses.
Two groups of eight horses were immobilized during 8 weeks. The first group (P-group) received a placebo, and the second group (T-group) received tiludronate 1 mg/kg by slow IV infusion. Both treatments were administered twice, 28 days apart. Immobilization consisted of stall rest with the left forelimb packed in a fiberglass cast. It was followed by a 4-week remobilization period and an 8-week standardized training protocol. One biomarker of bone resorption, the C-telopeptides of type I collagen cross-links (CTX-1) and one biomarker of bone formation, the bone isoenzyme of alkaline phosphatase (bone ALP), were assessed. Metacarpus III (MCIII) bone mineral density (BMD) and speed of sound (SOS) were evaluated respectively by dual energy X-ray absorptiometry (DEXA) and quantitative ultrasonography (QUS). Lameness was regularly assessed during the remobilization and training periods. Group- and time-related effects were tested by analysis of variance on repeated measurements.
A rapid, transient and significant decrease in CTX-1 concentration was seen after each treatment in the T-group only. No significant differences between groups were seen in the evolution of bone ALP activity. At the end of the experiment, the loss of MCIII BMD measured by DEXA in the immobilized limb was significantly less in the T-group than in the P-group. The MCIII SOS measured by QUS did not significantly vary within or between groups throughout the study.
Tiludronate was found to significantly reduce bone resorption during immobilization, as well as to prevent long-term osteopenia in the immobilized limb. Disuse osteopenia did not affect the lateral superficial cortex of MCIII.
替鲁膦酸盐是一种双膦酸盐,最近已被引入兽医学以治疗马的骨科疾病。本研究旨在评估其在马因石膏固定诱导的废用性骨质疏松实验模型中对骨代谢生化生物标志物以及骨密度和结构的影响。
两组各八匹马被固定8周。第一组(P组)接受安慰剂,第二组(T组)通过缓慢静脉输注接受1mg/kg替鲁膦酸盐。两种治疗均给药两次,间隔28天。固定包括将左前肢用玻璃纤维石膏包裹后圈栏休息。随后是4周的重新活动期和8周的标准化训练方案。评估了一种骨吸收生物标志物,即I型胶原交联C末端肽(CTX-1)和一种骨形成生物标志物,即碱性磷酸酶骨同工酶(骨ALP)。分别通过双能X线吸收法(DEXA)和定量超声检查(QUS)评估第三掌骨(MCIII)的骨矿物质密度(BMD)和声速(SOS)。在重新活动期和训练期定期评估跛行情况。通过重复测量方差分析测试组间和时间相关效应。
仅在T组每次治疗后观察到CTX-1浓度迅速、短暂且显著降低。两组之间骨ALP活性的变化无显著差异。在实验结束时,通过DEXA测量,T组固定肢体中MCIII BMD的损失明显低于P组。在整个研究过程中,通过QUS测量的MCIII SOS在组内或组间均无显著变化。
发现替鲁膦酸盐可显著减少固定期间的骨吸收,并预防固定肢体的长期骨质减少。废用性骨质减少未影响MCIII的外侧浅皮层。